“This is not normal for Novo Nordisk”
Novo Nordisk submitted an application for haemophilia drug N9-GP late last week, but Alm. Brand analyst Michael Friis Jørgensen does not expect a whole lot from the product for one very simple reason.
BY STEFAN SINGH KAILAY
Novo Nordisk usually performs better. That is the very plain assessment from Alm. Brand analyst Michael Friis Jørgense following last week’s announcement from the Danish-based drug group that it had submitted an application to the EMA for approval of its long-acting factor IX drug N9-GP to treat haemophilia B.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo CSO is pleased with product, disappointed by delay
For abonnenter
Novo enters partnership with IBM
For abonnenter
Analyst: New Novo drug can defend huge business
For abonnenter
